5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
BUY | BUY | BUY | SELL | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 0.04▼ | 0.04▼ | 0.04▲ | 0.04▲ | 0.05▼ |
MA10 | 0.04▼ | 0.04▲ | 0.04▲ | 0.04▲ | 0.06▼ |
MA20 | 0.04▲ | 0.04▲ | 0.04▲ | 0.05▼ | 0.14▼ |
MA50 | 0.04▲ | 0.04▲ | 0.04▲ | 0.06▼ | N/A |
MA100 | 0.04▲ | 0.04▼ | 0.04▼ | 0.16▼ | N/A |
MA200 | 0.04▼ | 0.05▼ | 0.05▼ | N/A | N/A |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.000▲ | 0.001▲ | 0.001▲ | 0.001▲ | 0.072▲ |
RSI | 57.174▲ | 59.540▲ | 60.535▲ | 41.581▼ | 13.696▼ |
STOCH | 83.722▲ | 88.613▲ | 80.456▲ | 25.358 | 6.341▼ |
WILL %R | -38.776 | -23.171▲ | -19.192▲ | -57.692 | -97.854▼ |
CCI | 42.256 | 101.821▲ | 143.062▲ | -16.224 | -67.671 |
Friday, April 26, 2024 12:28 PM
PaxMedica (NASDAQ: PXMD) , a leading biopharmaceutical company dedicated to advancing treatments for neurological disorders, was featured in the lat ...
|
Friday, April 26, 2024 11:30 AM
FDA approves Pfizer's Beqvez for adults with hemophilia B, offering a one-time treatment to produce FIX. Experience reduced bleeding frequency. Explore Pfizer's warranty program.
|
Friday, April 26, 2024 09:38 AM
Pfizer (PFE) said it has received FDA approval for its one-time gene therapy Beqvez for the treatment of certain adults with hemophilia B. Read more here.
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
26/04/24 | 0.041 | 0.0456 | 0.0391 | 0.044 | 49,385,718 |
25/04/24 | 0.0376 | 0.0386 | 0.0352 | 0.0381 | 10,355,057 |
24/04/24 | 0.0392 | 0.0399 | 0.0372 | 0.0379 | 5,661,972 |
23/04/24 | 0.04 | 0.041 | 0.039 | 0.0405 | 6,410,868 |
22/04/24 | 0.0393 | 0.0403 | 0.0362 | 0.0395 | 9,760,447 |
19/04/24 | 0.0421 | 0.0485 | 0.0393 | 0.04 | 35,361,478 |
18/04/24 | 0.0403 | 0.043 | 0.0385 | 0.04 | 11,795,811 |
17/04/24 | 0.043 | 0.045 | 0.039 | 0.042 | 7,687,999 |
16/04/24 | 0.0452 | 0.0455 | 0.04 | 0.043 | 6,688,009 |
15/04/24 | 0.0494 | 0.0494 | 0.0445 | 0.045 | 6,696,639 |
|
|
||||
|
|
||||
|
|